Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113601
Abstract: Syntenin stimulates exosome production and its expression is upregulated in many cancers and implicated in the spread of metastatic tumor. These effects are supported by syntenin PDZ domains interacting with syndecans. We therefore aimed to… read more here.
Keywords: syntenin pdz2; targeting syntenin; fragment based; drug design ... See more keywords